Priority Review Voucher Plan's Looming Sunset Shouldn't Dissuade Sponsors – FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Although FDA will be barred from issuing new rare pediatric disease priority review vouchers in March absent a legislative extension, agency is still encouraging sponsors to file designation requests.